(PharmaNewsWire.Com, December 04, 2018 ) This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 47+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 36+ active companies involved in the therapeutic development of the products.
Top Key Players: - Agenus Inc Alnylam AstraZeneca plc Aurigene BeiGene Bristol Myers Squibb Cellular Biomedicines Group Curis, Inc. CytomX Therapeutics EMD Serono, Inc Enumeral GlaxoSmithKline
Report Scope
-The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors -The report provides the marketed drugs information including its sales, development activities and details of patent expiry -The report provides the insight of current and future market for PD and PD-L1 inhibitors -The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information -Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type -The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling -The report also gives the information of dormant pipeline projects -Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages -Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
-Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage -Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors -Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine. -Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics -Developing strategic initiatives to support your drug development activities. -Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business. -Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope -Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies -Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline -Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
